Physician profile
Donna R Oneal
NPI 1902273055
$6,699.05
in general payments reported to CMS, 2019-2025
18 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 95% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $511 · 2022: $1,724 · 2023: $2,162 · 2024: $994 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.51 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,537.23 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,155.99 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $751.48 | 2021-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Grifols USA, LLC | $532.28 | 2021-2024 | Prolastin-C Liquid |
| Abbvie INC. | $470.03 | 2023-2025 | |
| Verona Pharma, INC. | $372.51 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $347.39 | 2021-2024 | Glassia |
| Genzyme Corporation | $310.62 | 2022-2025 | |
| Amgen INC. | $292.85 | 2022-2024 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $247.68 | 2024-2025 | Cobenfy |
| Regeneron Healthcare Solutions, INC. | $223.57 | 2021-2023 | Dupixent |
| Electromed, INC. | $141.12 | 2022-2023 | Smartvest |
| Pfizer INC. | $97.54 | 2025 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Pulmonx Corporation | $66.56 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.31 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $18.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Oneal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.